14 June 2024
Swissmedic publishes its Annual Report for 2023
On 7 June 2024 the Federal Council ratified Swissmedic’s 2023 reporting and approved the Annual Report. In addition to performance and financial overviews, this includes information about the wide-ranging activities of the Swiss Agency for Therapeutic Products. Swissmedic successfully completed the first year in the new 2023–2026 strategy period.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting